EZH2 activity is up-regulated in cancer due to gain-of-function mutations, down-regulation of its suppressors, amplification of gene expression or increase of protein abundance by oncogenic pathways such as PI3K-AKT and MEK-ERK, post-transcriptional and post-translational modifications. The gene discussed is AKT1; the disease is cancer.